MYC/MIZ1 suppression of lysosomal protein degradation drives immune evasion in pancreatic ductal adenocarcinoma
Krenz, B.; Kannan, T.; Mattavelli, G.; Schmitz, W.; Gebhardt-Wolf, A.; John, M.; Cetkovic, A.; Aintablian, A.; Caviccioli, S.; Nowak, L.; Bopp, S.; Schuelein-Voelk, C.; Ade, C. P.; Herold, S.; Bender, J.; Warscheid, B.; Sers, C.; Zukowska, M.; Vaeth, M.; Buechel, G.; Zindy, F.; Pruett-Miller, S. M.; Roussel, M. F.; Saur, D.; Riedel, A.; Eilers, M.
Show abstract
The MYC oncoprotein promotes immune evasion of pancreatic ductal adenocarcinoma (PDAC), but the underlying molecular mechanisms are not fully understood. Here we show that MYC protects PDAC tumors from CD4+ T cell-dependent elimination. Single cell sequencing shows that MYC suppression in tumor cells increases amino acid availability and broadly activates amino acid-responsive gene expression programs in immune cell populations. This occurs because MYC-driven uptake depletes free amino acids from tumor interstitial fluid and plasma, while MYC compromises macropinocytosis and autophagy, both of which depend on lysosomal protein degradation. MYC engages the POZ/BTB transcription factor MIZ1 to suppress lysosomal genes regulated by the TFE3/TFEB/MITF network or by free MIZ1, thereby inhibiting lysosomal protein degradation. An orthogonal genetic model enabling transient, selective inhibition of amino acid uptake in tumor cells recapitulates the effects of MYC depletion on amino acid levels in the tumor microenvironment and induces complete, CD4+ T cell-dependent tumor eradication with long-term survival. We propose that MYC-mediated, cell-autonomous disruption of lysosome function coupled to non-cell-autonomous protection from immune clearance allows MYC-low cells to benefit from MYC-high neighbors, such that intratumoral heterogeneity in MYC expression confers a selective advantage to the entire tumor. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=141 SRC="FIGDIR/small/740267v1_ufig1.gif" ALT="Figure 1"> View larger version (53K): org.highwire.dtl.DTLVardef@1fd5c3corg.highwire.dtl.DTLVardef@b27ba6org.highwire.dtl.DTLVardef@1d40603org.highwire.dtl.DTLVardef@d6e643_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 97%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 97%
- Combinatorial immunotherapies overcome MYC-driven immune evasion 97%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1 97%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 96%
- Extracellular 2’3’-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1 96%
Similar papers in this journal
- Neuroblastoma formation requires unconventional CD4 T cells and myeloid amino acid metabolism 97%
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities 96%
- Age-associated modulation of TREM1/2- expressing macrophages promotes melanoma progression and metastasis 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.